Neuren Pharmaceuticals Ltd (NEU) — Cash Flow Quality Index
Neuren Pharmaceuticals Ltd (NEU) has a Cash Flow Quality Index of 8.54x as of June 2025. Operating cash flow of AU$128.31 Million exceeds net income of AU$15.03 Million, indicating high earnings quality where cash backs reported profits. Explore NEU debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Neuren Pharmaceuticals Ltd Cash Flow Quality Index (2009–2024)
Historical Cash Flow Quality Index for Neuren Pharmaceuticals Ltd across 6 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see NEU operating cash flow.
Annual Cash Flow Quality Index for Neuren Pharmaceuticals Ltd (2009–2024)
Year-by-year earnings quality comparison for Neuren Pharmaceuticals Ltd.
| Year | Quality Index | Operating CF (AUD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | -0.08x | AU$-11.27 Million | AU$142.04 Million | ▼ -106.7% |
| 2023 | 1.18x | AU$184.93 Million | AU$157.08 Million | ▼ -94.0% |
| 2022 | 19.56x | AU$3.60 Million | AU$184.00K | ▲ +838.0% |
| 2018 | 2.09x | AU$6.41 Million | AU$3.07 Million | ▲ +222.7% |
| 2017 | -1.70x | AU$-5.59 Million | AU$3.29 Million | ▲ +86.8% |
| 2009 | -12.93x | AU$-1.29 Million | AU$99.56K | — |